Unlock instant, AI-driven research and patent intelligence for your innovation.

Agent for induction/maintenance of remission

A technology of inhibitors and antagonists, which is applied in the field of remission and maintenance therapeutic agents for immune diseases, can solve the problems of non-disclosure and the like, and achieve the effect of alleviating immune diseases

Inactive Publication Date: 2011-07-13
KYORIN PHARMA CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, Patent Document 1 uses diaryl sulfide or diaryl ether compounds with 2-amino-1,3-propanediol structure in combination with anti-inflammatory drugs such as methotrexate from the beginning, but it is related to the alleviation of immune diseases. Thereafter, switching from anti-inflammatory drugs to diaryl sulfide or diaryl ether compounds to maintain remission is completely undisclosed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for induction/maintenance of remission
  • Agent for induction/maintenance of remission
  • Agent for induction/maintenance of remission

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Rat Adjuvant Arthritis Model

[0058] 0.05 mL (0.6 mg / rat) of M. butyricum dead bacteria (12 mg / mL) suspended in liquid paraffin was injected intradermally into the dorsum of the right hind limb of 8-week-old LEW / CrlCrlj female rats (Charles-River, Japan). ), triggering arthritis (Day 0). The drug solution prepared with 0.5% methylcellulose (0.5% MC) was administered to the gastrointestinal tract at 0.5 mL / 100 g rat body weight. The adjuvant control was given only 0.5% MC. On days 0 to 10, methotrexate (MTX, Sigma) was given daily at 0.1 mg / kg once a day. Switch to (R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methyl-1-pentanol hydrochloride from day 11 Salt (hereinafter referred to as Compound 1, 1 mg / kg) was administered once a day until the 24th day. The evaluation of arthritis was carried out as follows: Use a volumetric measuring instrument (MK-550, Muromachi Machinery) to measure the volume of the left and right hind limbs on the 0th, 8th,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a method for inducing / maintaining remission of an immune disease, which can reduce serious adverse side effects and stress in a patient. After the induction of remission of an immune disease with a biological substance or a nucleic acid synthesis inhibitor, a sphingosine-1-phosphate receptor agonist is used.

Description

technical field [0001] The present invention relates to a remission maintenance therapeutic agent and a remission maintenance therapy for immune diseases. Background technique [0002] In recent years, the treatment of immune diseases such as rheumatoid arthritis has been greatly improved, and the treatment strategy itself has been re-established. The expansion of antirheumatic drugs such as methotrexate showing excellent clinical effects, and the introduction of biological agents showing epoch-making clinical effects and joint destruction inhibitory effects are the driving forces. But the reality is that it is almost impossible to go from remission to discontinuation of treatment, and these drugs must be continued after induction of remission. In addition, antirheumatic drugs such as methotrexate are sometimes found to have serious side effects, so regular inspections are necessary, and biological drugs are not preferred in terms of patient QOL because they are administere...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/137A61K31/42A61K31/519A61K31/7056A61K38/00A61P1/04A61P11/06A61P13/12A61P17/06A61P19/02A61P21/04A61P25/00A61P29/00A61P37/02A61P37/08A61P43/00
CPCA61K31/7056A61K31/42A61K31/519A61K38/1793A61K31/137A61K45/06A61P1/04A61P11/06A61P13/12A61P17/06A61P19/02A61P21/04A61P25/00A61P29/00A61P37/00A61P37/02A61P37/06A61P37/08A61P43/00A61K2300/00
Inventor 栗山和彦加后智之安江德太郎
Owner KYORIN PHARMA CO LTD